| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Whitehawk Therapeutics, Inc. | Director | Stock Option (right to buy) | 40,006 | 12 Jun 2025 | Direct | ||
| Turning Point Therapeutics, Inc. | EVP and Chief Medical Officer | Common Stock | 0 | $76.00 | 17 Aug 2022 | Direct | |
| Turning Point Therapeutics, Inc. | EVP and Chief Medical Officer | Stock Option (right to buy) | 0 | 17 Aug 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| WHWK | Whitehawk Therapeutics, Inc. | 12 Jun 2025 | 1 | $0 | 4 | Director | 16 Jun 2025, 16:58 |
| WHWK | Aadi Bioscience, Inc. | 12 Jun 2024 | 1 | $0 | 4 | Director | 14 Jun 2024, 16:10 |
| WHWK | Aadi Bioscience, Inc. | 27 Mar 2023 | 1 | $0 | 4 | Director | 29 Mar 2023, 16:20 |
| WHWK | Aadi Bioscience, Inc. | 27 Mar 2023 | 0 | $0 | 3 | Director | 29 Mar 2023, 16:18 |
| /report/000120919122046264-hirmand-mohammad-2022-08-17 | Turning Point Therapeutics, Inc. | 17 Aug 2022 | 4 | -$3,137,584 | 4 | EVP and Chief Medical Officer | 17 Aug 2022, 16:26 |
| /report/000120919122008980-hirmand-mohammad-2022-02-09 | Turning Point Therapeutics, Inc. | 09 Feb 2022 | 4 | -$24,285 | 4 | EVP & Chief Medical Officer | 11 Feb 2022, 17:08 |